在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Human pulmonary activation regulated chemokine,PARC ELISA Kit

  • 中文名稱:
    人肺部活化調節趨化因子(PARC/CCL18)酶聯免疫試劑盒
  • 貨號:
    CSB-E09941h-IS
  • 規格:
    96T/48T
  • 價格:
    ¥3200/¥2500
  • 其他:

產品詳情

  • 產品描述:
    人肺部活化調節趨化因子(PARC/CCL18)酶聯免疫試劑盒(CSB-E09941h-IS)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿、組織勻漿樣本中的CCL18含量。CCL18是一種重要的靶點。它在炎癥反應、免疫調節等生理病理過程中發揮作用。研究表明其能參與腫瘤微環境的塑造,促進腫瘤細胞的增殖、轉移等。對CCL18作用機制的深入研究,有助于開發針對該靶點的治療方法以對抗相關疾病。試劑盒檢測范圍為7.8 pg/mL-500 pg/mL,靈敏度為3.9 pg/mL。用于探索肺部疾病機制、慢性炎癥反應或腫瘤微環境中的免疫調控研究。科研人員可通過評估不同病理模型或藥物干預下 CCL18 的動態變化,為呼吸系統疾病、免疫相關研究提供定量數據支持。本品僅用于科研,不用于臨床診斷,產品具體參數及操作步驟詳見產品說明書。
  • 別名:
    Alternative macrophage activation associated CC chemokine 1 ELISA Kit; Alternative macrophage activation-associated CC chemokine 1 ELISA Kit; AMAC-1 ELISA Kit; AMAC1 ELISA Kit; CC chemokine PARC ELISA Kit; CCL18 ELISA Kit; CCL18(4-69) ELISA Kit; CCL18_HUMAN ELISA Kit; CKb7 ELISA Kit; DC-CK1 ELISA Kit; DCCK1 ELISA Kit; DCCK1 ELISA Kit; Dendritic cell chemokine 1 ELISA Kit; Macrophage inflammatory protein 4 ELISA Kit; MIP-4 ELISA Kit; MIP4 ELISA Kit; PARC ELISA Kit; Pulmonary and activation regulated chemokine ELISA Kit; Pulmonary and activation-regulated chemokine ELISA Kit; SCYA18 ELISA Kit; Small inducible cytokine A18 ELISA Kit; Small inducible cytokine A18 ELISA Kit; Small-inducible cytokine A18 ELISA Kit
  • 縮寫:
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類型:
    serum, plasma, tissue homogenates
  • 檢測范圍:
    7.8 pg/mL-500 pg/mL
  • 靈敏度:
    3.9 pg/mL
  • 反應時間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測波長:
    450 nm
  • 研究領域:
    Immunology
  • 測定原理:
    quantitative
  • 測定方法:
    Sandwich
  • 精密度:

    Intra-assay Precision (Precision within an assay): CV%<8%

    Three samples of known concentration were tested twenty times on one plate to assess.

    Inter-assay Precision (Precision between assays): CV%<10%

    Three samples of known concentration were tested in twenty assays to assess.

  • 線性度:

    To assess the linearity of the assay, samples were spiked with high concentrations of human PARC in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

     

    Sample

    Serum(n=4)

    1:200

    Average %

    101

    Range %

    94-108

    1:400

    Average %

    97

    Range %

    91-105

    1:800

    Average %

    90

    Range %

    85-96

    1:1600

    Average %

    93

    Range %

    85-100

  • 回收率:

    The recovery of human PARC spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

    Sample Type

    Average % Recovery

    Range

    Serum (n=5)

    91

    86-98

    EDTA plasma (n=4)

    96

    90-103

  • 標準曲線:

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

    pg/ml

    OD1

    OD2

    Average

    Corrected

    500

    2.636

    2.734

    2.685

    2.590

    250

    1.697

    1.657

    1.677

    1.582

    125

    1.043

    1.108

    1.076

    0.980

    62.5

    0.614

    0.629

    0.622

    0.526

    31.2

    0.374

    0.381

    0.378

    0.282

    15.6

    0.237

    0.253

    0.245

    0.150

    7.8

    0.193

    0.184

    0.189

    0.093

    0

    0.096

    0.095

    0.096

     

  • 數據處理:
  • 貨期:
    3-5 working days

產品評價

靶點詳情

  • 功能:
    Chemotactic factor that attracts lymphocytes but not monocytes or granulocytes. May be involved in B-cell migration into B-cell follicles in lymph nodes. Attracts naive T-lymphocytes toward dendritic cells and activated macrophages in lymph nodes, has chemotactic activity for naive T-cells, CD4+ and CD8+ T-cells and thus may play a role in both humoral and cell-mediated immunity responses.
  • 基因功能參考文獻:
    1. miR-128 interacts with CCL18 3'UTR, reducing its expression in malignant melanoma. PMID: 30025750
    2. AMAP1 mediated CCL18-induce activation of NF-kappaB and promoted breast cancer metastasis. PMID: 28834540
    3. results of the study indicate that there could be a relationship between the expression of CCL-18 in nasal turbinate mucosa and the severity of allergic rhinitis PMID: 30102123
    4. chemokine CCL18 can be a mediator of peritoneal membrane failure associated with peritonitis episodes as well as providing a new potential therapeutic target. PMID: 29850544
    5. CCL18 was up-regulated in diffuse large B cell lymphoma and related to poor prognosis PMID: 29504526
    6. Serum C-C motif chemokine ligand 18 (CCL18) was elevated in patients with epithelial ovarian cancer (EOC) and could serve as a new tumor biomarker, which also predicted a poor survival of the patient. PMID: 29036787
    7. In advanced lung adenocarcinoma, infiltration of CCL18(+) tumor-associated macrophages (TAMs) was increased and higher expression of CCL18 by TAMs was associated with a favorable prognosis in lymph-node positive NSCLC PMID: 29970512
    8. This study study discovered a positive feedback loop between CTGF and CCL18 in hepatocellular carcinoma metastasis. PMID: 28837877
    9. All patients with NPC1 mutations had high ChT activity, high CCL18/PARC concentrations and/or Niemann-Pick disease type C suspicion index scores >/=70. PMID: 28222799
    10. findings suggest that these pulmonary markers could be useful to assess CAP severity and, especially YKL-40 and CCL18 by helping predict CAP caused by atypical pathogens PMID: 29324810
    11. PARC activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing. PMID: 28234357
    12. Matrigel invasion assays revealed that tumor ECM-educated macrophages efficiently stimulated cancer cell invasion through a mechanism involving CCL18. PMID: 28209528
    13. Our results indicate that CCL18 acts in an autocrine manner via Akt activation to stimulate oral squamous cell carcinoma cell growth and invasion during disease progression PMID: 26919103
    14. Our data indicate that hypoxic inhibition of JMJD3 activity reduces demethylation of H3K27me3, nucleosome removal, and hence induction of the STAT6 target gene CCL18, while induction of other STAT6-inducible genes such as SPINT2 remained unaffected by JMJD3. PMID: 27737800
    15. There was no association between serial CCL18 concentrations with tumor response and overall survival. PMID: 28957436
    16. CCL-18 is a promising biomarker in COPD, as it is associated with frequency of exacerbations, particularly with severe COPD exacerbations requiring hospitalization, as well as with functional parameters and symptom scores. PMID: 28115842
    17. Data suggested that CCL18 upregulated Slug expression to promote epithelial-mesenchymal transition (EMT) and stem cell-like features by activating the mTOR pathway in oral cancer. PMID: 28574664
    18. An increased lung protein expression of PARC in chronic obstructive pulmonary disease patients PMID: 28545096
    19. CCL18 can increase the invasive ability of non-small cell lung cancer cells by binding to its receptor Nir1. PMID: 26756176
    20. Results demonstrate that high levels of CCL18 are present in ovarian cancer (OC) ascites and that CCL18 is an important component of ascites for the ascites-mediated migration of OC cells. Ascites and CCL18 stimulate the phosphorylation and expression of Pyk2, which is critical for mediated CCL18-induced migration. PMID: 27613122
    21. Data suggest that circulating CCL18 and abdominal subcutaneous white adipose tissue-secreted CCL18 correlates with insulin resistance and metabolic syndrome risk score; because CCL18 is macrophage-specific and associates with adipose immune gene expression, it may constitute a marker of adipose tissue inflammation (panniculitis). PMID: 27459538
    22. Cytomegalovirus replication in the allograft causes an intrapulmonary increase of CCL-18 and CCL-20 and a systemic rise of CCL-20 serum levels. Strong intrapulmonary CCL-18 responses are associated with symptomatic HCMV disease, proposing that CCL-18 BALF levels could serve as a marker. PMID: 26910332
    23. Study determined that CCL18 expression was up-regulated in ovarian carcinoma suggesting that CCL18 may play an important role in the pathogenicity of epithelial ovarian cancer through the induction of regulators and the activation of signaling pathways including mTORC2 signaling pathways. PMID: 26457987
    24. CCL18 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
    25. release of CCL18 with greater non-small cell lung cancer tumor size is most likely due to the accompanied growth of leukocyte infiltrate PMID: 27630310
    26. this study shows that CCL18 has a correlation with cardiac function in patients with acute anterior myocardial infarction PMID: 27350631
    27. our findings establish a signaling role for CCL18 in gastric cancer cells and identify that the CCL18/ERK1/2/NF-kappaB signaling pathway is essential for tumor invasiveness in gastric cancer cells. PMID: 26242263
    28. CCL18 enhances hepatocellular carcinoma (HCC) cell migration, invasion, and epithelial-mesenchymal transition (EMT) through the expression of PITPNM3 and the activation of the NF-kappaB signaling pathway. PMID: 26449829
    29. our findings suggest that CCL18 released from tumor-associated macrophages promotes angiogenesis and tumor progression in breast cancer. PMID: 26416449
    30. Findings suggest that down-regulation of miR98 and miR27b promotes CCL18-mediated invasion and migration of breast cancer cells. PMID: 26244871
    31. CCL18 is significantly up-regulated in breast cancer vs benign tumors or normal breast. It increased with the size of tumors, the number of lymph node metastasis, and advancing tumor stage. PMID: 26294068
    32. A common CCL18 polymorphism together with intraventricular hemorrhage had an additive influence on cerebral palsy susceptibility. PMID: 26113374
    33. The CCL18 levels in serum and synovial fluid are correlated with the severity of osteoarthritis. PMID: 25794928
    34. Combined functions of CCL18 in mesenchymal and cancer cells might accelerate the progression of PDAC by promoting the epithelial-mesenchymal transition, invasion and migration of pancreatic cancer cells. PMID: 25502147
    35. Increased CCL18 levels characterize chronic Pseudomonas aeruginosa infection and pulmonary obstruction in patients with cystic fibrosis. PMID: 25142483
    36. upregulation of CCL18 may be involved in the malignant progression of prostate cancer. PMID: 25197632
    37. CCL-18 and IGFBP-6 were identified as new potential serum biomarkers for prostate cancer. PMID: 24747338
    38. CCL18 expression was positively correlated with malignancy in EC. PMID: 25275026
    39. Pyk2 and Src are important in CCL18-induced breast cancer metastasis PMID: 24142406
    40. CCL18 is an antimicrobial protein with bacteriocidal activity against E. coli and S. aureus. PMID: 12949249
    41. CCL18 from tumor-associated macrophages induces cancer cell epithelial-mesenchymal transition, forming a positive feedback loop, in coculture systems and humanized mice. PMID: 24823638
    42. Further development of A1AT as a diagnostic biomarker for BCa is warranted. PMID: 24011266
    43. the Cys10-Cys34 disulfide bond is involved in the function of CCL18. PMID: 23742785
    44. genetic polymorphism is associated with lung function in Hutterites, who are a founder population of European descent in North America PMID: 23932459
    45. In patients with systemic sclerosis-related interstitial lung disease, CCL18 was a predictor of short-term decline in forced vital capacity. It was not a longterm prognostic indicator. PMID: 23588945
    46. Data indicate that PYK2 N-terminal domain interacting receptor 1 (Nir1) could induce epithelial-mesenchymal transition by stabilising Snail via the PI3K/Akt/GSK3beta/Snail signalling pathway through binding to CCL18. PMID: 24001613
    47. this review focuses on the potential role, in asthma and lung immunity, of CCL18 a chemokine both constitutively expressed at high levels in the lung and induced in inflammatory conditions PMID: 23786278
    48. Identification of human CCR8 as a CCL18 receptor. PMID: 23999500
    49. A high CCL18 level might be an independent biomarker for predicting better survival of patients with colorectal cancer. PMID: 23433718
    50. CCL18 may be an interesting therapeutic target for NSCLC PMID: 23349697

    顯示更多

    收起更多

  • 亞細胞定位:
    Secreted.
  • 蛋白家族:
    Intercrine beta (chemokine CC) family
  • 組織特異性:
    Expressed at high levels in lung, lymph nodes, placenta, bone marrow, dendritic cells present in germinal centers and T-cell areas of secondary lymphoid organs and macrophages derived from peripheral blood monocytes. Not expressed by peripheral blood mono
  • 數據庫鏈接:

    HGNC: 10616

    OMIM: 603757

    KEGG: hsa:6362

    STRING: 9606.ENSP00000004921

    UniGene: Hs.143961



主站蜘蛛池模板: 国产人妻久久精品二区三区老狼| 日韩欧美偷拍高跟鞋精品一区| 国产老熟女狂叫对白| 天天夜碰日日摸日日澡性色av| 一本一道波多野结衣av黑人| 直接观看黄网站免费视频 | 婷婷五月综合激情中文字幕| 国产成人亚洲综合网站小说| 久久精品国产99国产精2021| 强奷乱码中文字幕熟女一| 大肉大捧一进一出好爽动态图 | 日本三级韩国三级欧美三级| 国产美女爽到喷出水来视频| 人澡人人澡人人澡欧美| 久久av一区二区三区| 成人性生交大片免费看r老牛网站| 337p粉嫩日本欧洲亚福利| 欧美自拍亚洲综合图区| 婷婷丁香五月中文字幕| 亚洲va久久久噜噜噜久久天堂| 国产免费人成在线视频app| 国产精品麻豆成人av电影艾秋| 国产成人综合久久亚洲精品| 亚洲中文字幕无码人在线| 乱码精品一区二区三区| 人妻丰满熟妇av无码区| 天堂а√在线中文在线新版| 亚洲免费综合色在线视频| 亚洲人成网站18禁止大app| 久久亚洲中文字幕无码| 2017亚洲天堂最新地址| 亚洲中文字幕乱码熟女在线| 一本加勒比波多野结衣| 粗大挺进尤物人妻中文字幕| 久久天天躁狠狠躁夜夜夜| 97精品超碰一区二区三区| 97免费人妻无码视频| 免费刺激性视频大片区| 色婷婷亚洲精品综合影院| 用舌头去添高潮无码视频| 久久久无码人妻精品无码|